Document text
Principal Investigator: Tongqing Zhou
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2024
Award: $1,554,806
Funding agency: National Institute of Allergy and Infectious Diseases
Highly effective neutralizing antibodies could have utility in the prevention or treatment of infection from HIV-1, influenza virus, Lassa virus, and other human pathogens, including the recently emerged SARS-CoV-2. Much of our work with neutralizing antibodies has focused on identifying, characterizing and in many cases improving naturally elicited antibodies. Improved HIV-1 neutralizing antibodies include versions of CD4-binding site-directed antibodies capable of neutralizing over 95% of HIV strains, and some of these have been manufactured and assessed clinically. We are also working in collaboration with other groups to identify and to characterize effective neutralizing antibodies against other human pathogens. Overall, our antibody-related work involves understanding antibodies for vaccine insights and improving antibodies, as possible therapeutic agents against HIV-1, SARS-CoV-2, influenza virus, and other human pathogens.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Antibodies><Antigenic Determinants><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Binding Determinants><Binding Sites><COVID-19 virus><COVID19 virus><Cell Ontogeny><Clinical><CoV-2><CoV2><Collaborations><Combining Site><Epitopes><HIV><HIV Infections><HIV-1><HIV-I><HIV1><HTLV-III Infections><HTLV-III-LAV Infections><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><Human immunodeficiency virus 1><Immune system><Infection prevention><Influenza Virus><LAV-HTLV-III><Lassa fever virus><Lassa virus><Lymphadenopathy-Associated Virus><Pathway interactions><Prevent infection><Prevention><Reactive Site><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Structure><Therapeutic Agents><Vaccine Design><Vaccines><Virus-HIV><Work><Wuhan coronavirus><clinical applicability><clinical application><coronavirus disease 2019 virus><coronavirus disease-19 virus><hCoV19><human pathogen><improved><influenzavirus><insight><manufacture><nCoV2><neutralizing antibody><pathogen><pathway><vaccine antibodies><vaccine induced antibodies><vaccine-induced antibodies>